Cargando…

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

Objective To measure the effectiveness of the quadrivalent human papillomavirus (HPV) vaccine against cervical abnormalities four years after implementation of a nationally funded vaccination programme in Queensland, Australia. Design Case-control analysis of linked administrative health datasets. S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crowe, Elizabeth, Pandeya, Nirmala, Brotherton, Julia M L, Dobson, Annette J, Kisely, Stephen, Lambert, Stephen B, Whiteman, David C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942076/ https://www.ncbi.nlm.nih.gov/pubmed/24594809 http://dx.doi.org/10.1136/bmj.g1458

Ejemplares similares

Cancers in Australia in 2010 attributable to the consumption of alcohol
por: Pandeya, Nirmala, et al.
Publicado: (2015)

Cancers in Australia in 2010 attributable to tobacco smoke
por: Pandeya, Nirmala, et al.
Publicado: (2015)

Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia
por: Brotherton, Julia M.L., et al.
Publicado: (2015)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

Patient and Tumour Characteristics of Keratoacanthoma in a Large, Community-based Cohort Study from Queensland, Australia
por: KOLMODIN, Agnes, et al.
Publicado: (2021)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Cancers in Australia in 2010 attributable to insufficient physical activity
por: Olsen, Catherine M, et al.
Publicado: (2015)

Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia
por: Rodriguez-Acevedo, Astrid J., et al.
Publicado: (2021)

Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men
por: Swedish, Kristin A., et al.
Publicado: (2014)

Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma
por: Thrift, Aaron P., et al.
Publicado: (2012)

Psychosocial impact of testing human papillomavirus positive in Australia's human papillomavirus‐based cervical screening program: A cross‐sectional survey
por: Chadwick, Verity, et al.
Publicado: (2022)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy
por: Jordan, Susan J, et al.
Publicado: (2015)

Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives
por: Jordan, Susan J, et al.
Publicado: (2015)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study
por: Leval, Amy, et al.
Publicado: (2013)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
por: Hernandez-Aguado, Juan J., et al.
Publicado: (2022)

A case of acute disseminated encephalomyelitis following human papillomavirus quadrivalent vaccination
por: Lee, Mina, et al.
Publicado: (2022)

Incidence of in Situ vs Invasive Melanoma: Testing the “Obligate Precursor” Hypothesis
por: Olsen, Catherine M, et al.
Publicado: (2022)

Cancers in Australia in 2010 attributable to total breastfeeding durations of 12 months or less by parous women
por: Jordan, Susan J, et al.
Publicado: (2015)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
por: Jit, Mark, et al.
Publicado: (2011)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types
por: Tanton, Clare, et al.
Publicado: (2017)

Kintsugi: Comprehensive repair of Australia’s fractured psychiatric care system
por: Looi, Jeffrey CL, et al.
Publicado: (2023)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021
por: Gordon, Louisa G., et al.
Publicado: (2022)

A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
por: Geier, David A., et al.
Publicado: (2014)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
por: Diaz, Maria Lina
Publicado: (2010)

Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia
por: Aponte-González, Johanna, et al.
Publicado: (2013)

1050 Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)
por: Lievano, Fabio, et al.
Publicado: (2014)

Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine
por: Schlecht, Nicolas F., et al.
Publicado: (2019)

Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report
por: Kong, Kangjie, et al.
Publicado: (2021)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers
por: Lawrence, David, et al.
Publicado: (2013)

Implementation of Australia’s primary human papillomavirus (HPV) cervical screening program: The STakeholders Opinions of Renewal Implementation and Experiences Study
por: Brotherton, Julia M.L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_65i4bu6krqh89vg64bs1b5hf4b